Intest Res > Volume 17(3); 2019 > Article |
|
FINANCIAL SUPPORT
This work was supported by the Deutsche Forschungsgemeinschaft, Germany (Heisenberg Program).
CONFLICT OF INTEREST
J.W. received speakers honoray and/or consultant fees from Takeda, AbbVie, MSD, Ferring, Roche, Novartis, Janssen. T.K. received speakers honoray and/or consultant fees from Takeda, AbbVie, MSD, Novartis, Janssen. M.G. received speakers honoray and/or consultant fees from Takeda, AbbVie, MSD, Novartis, Janssen. Except for that, no potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION
Conceptualization: Saman S, Klag T, Wehkamp J. Methodology: Saman S, Klag T, Wehkamp J. Formal analysis: Saman S, Klag T, Wehkamp J, Wendler J, Goetz M. Funding acquisition: Wehkamp J, Malek NP. Project administration: Saman S, Klag T. Visualization: Saman S, Klag T, Wehkamp J, Wendler J, Malek NP. Writing - original draft: Saman S, Klag T, Wehkamp J. Writing - review and editing: all. Approval of final manuscript: all authors.
Characteristic | Value (n = 13) |
---|---|
Sex | |
Male | 10 (77) |
Female | 3 (23) |
Mean age (yr) | 36.3 |
Median weight (kg) | 64.0 |
Mean duration of disease (yr) | 11.1 |
Median CRP (mg/dL) (n = 11)a | 0.8 |
CRP level at baselinea | |
≤ 0.5 mg/dL | 4 (31) |
> 0.5 mg/dL | 7 (54) |
CDAI at baseline | |
≤ 150 | 3 (23) |
151-220 | 10 (77) |
CD drugs at baseline | |
Aminosalicylate drug | 2 (15) |
Glucocorticoid | 5 (38) |
Failure of previous treatment | |
Any immunomodulatory drugs | 11 (85) |
Anti-TNFs at baseline | |
1 | 10 (77) |
>1 | 1 (7) |
Anti-TNF+vedolizumab at baseline | 2 (75) |
Failure criteria met | |
Primary nonresponse | 5 (38) |
Secondary nonresponse within 8 months | 0 |
Unacceptable side effects | 1 (7) |
Stoma | 3 (23) |
Characteristic | Value (n = 28) |
---|---|
Sex | |
Male | 9 (32) |
Female | 19 (68) |
Mean age (yr) | 35.5 |
Median weight (kg) | 65.0 |
Mean duration of disease (yr) | 14.3 |
Median CRP (mg/dL) (n = 24)a | 1.3 |
CRP level at baselinea | |
≤ 0.5 mg/dL | 9 (32) |
> 0.5 mg/dL | 15 (53) |
CDAI at baseline | |
221-450 | 25 (89) |
> 450 | 3 (11) |
CD drugs at baseline | |
Aminosalicylate drug | 5 (18) |
Glucocorticoid | 10 (36) |
Failure of previous treatment | |
Any immunomodulatory drugs | 27 (96) |
Anti-TNFs at baseline | |
1 | 11 (39) |
>1 | 9 (32) |
Anti-TNF+vedolizumab at baseline | 8 (29) |
Biologicals naive | 3 (11) |
Failure criteria met | |
Primary nonresponse | 9 (32) |
Secondary nonresponse within 8 months | 3 (11) |
Unacceptable side effects | 1 (3) |
Stoma | 1 (3) |